Compare SSBI & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SSBI | MXCT |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | United States |
| Employees | 103 | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.6M | 93.0M |
| IPO Year | N/A | 2021 |
| Metric | SSBI | MXCT |
|---|---|---|
| Price | $13.50 | $1.02 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 3.9K | ★ 562.2K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $13.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.20 | $0.64 |
| 52 Week High | $14.00 | $2.40 |
| Indicator | SSBI | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 47.48 | 69.63 |
| Support Level | $12.78 | $0.77 |
| Resistance Level | $13.58 | $1.81 |
| Average True Range (ATR) | 0.15 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 65.49 | 65.43 |
Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.